OPEN ACCESS Freely available online

Clinical Microbiology: Open Access

Editorial

Editorial on Pulmonary Fibrosis Prognosis

Michal Araski*

Department of Otolaryngology, Poznan University of Medical Sciences, Poznan, Poland

Pulmonary fibrosis is a chronic and progressive lung condition in which the air sacs present inside the lungs, called as alveoli, become scarred and rigid, making breathing and getting enough oxygen into the bloodstream difficult. It may lead to respiratory failure, heart failure, or other complications in the long run. Idiopathic pulmonary fibrosis refers to cases of pulmonary fibrosis that occur without a known cause. Environmental risks and autoimmune disorders are also factoring in several instances. Some patients' pulmonary fibrosis is caused by medication-induced lung damage. In other, more unusual cases, genetics may predispose some patients to developing the disorder. It is believed that genetics may play a role in the development of pulmonary fibrosis. Pulmonary fibrosis which caused by inheritance, such is called as familial pulmonary fibrosis. Patients with pulmonary fibrosis have varying prognoses based on their age, physical health, lifestyle habits, and the seriousness of the disease at the time of diagnosis. There are currently no proven methods for preventing pulmonary fibrosis, particularly because the cause of the disease is often unknown. As a result, the only way to stop pulmonary fibrosis is to avoid future complications such as smoking, which may help reduce the risk of developing the condition and to have routine medical exams. Researchers conclude that pulmonary fibrosis is caused by a combination of lung irritants such as certain chemicals, smoking, and infections, as well as genetics and immune system function. There are four stages in pulmonary fibrosis, mild, moderate, medium, and very severe pulmonary fibrosis. The severity of a patient's symptoms and their lung capacity decide their disease level. Patients lose lung capacity as the disease progresses, and in severe cases, they may be unable to breathe without assistance. It's difficult to estimatethe prevalence of pulmonary fibrosis in general since it can coexist with other conditions like the collagen vascular diseases described earlier, as well as occupational exposures and drug reactions. Patients with pulmonary fibrosis are at risk for other health problems such as heart failure, stroke, pulmonary embolism, and lung infections as the disease progresses. Other tissues don't get the oxygen they need if the lungs are weak, and scar tissue makes the lungs more vulnerable to infection. Patients with pulmonary fibrosis should attend pulmonary therapy, where they can learn about the condition, available medications, and breathing strategies, as well as be put on an exercise regimen to help strengthen their lungs and delay disease progression. Pulmonary fibrosis does not always develop in the same way. The disease may progress slowly in some patients before suddenly speeding up and leading to respiratory failure. As a result, disease development must be closely controlled in order to enhance prognosis. Every person with pulmonary fibrosis has a different experience with the disease. Some people's symptoms and overall health improve slowly over time, while others' symptoms and overall health quickly deteriorate. There is no treatment for pulmonary fibrosis. Current therapies aim to avoid more lung scarring, alleviate symptoms, and keep you active and healthy. Pneumococcal fibrosis can be stipulated or prescribed with immunosuppressive drugs. Lung transplantation may be needed in extreme cases. prevention and treatment.

Correspondence to: Michal Araski, Department of Otolaryngology, Poznan University of Medical Sciences, Poznan, Poland, E-mail: marab@kielce.pl

Received: May 7, 2021; **Accepted:** May 22, 2021; **Published:** May 29, 2021

Citation: Araski M. (2021) Editorial on Pulmonary Fibrosis Prognosis. Clin Microbiol. 10:200